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Abstract
Coronary stent thrombosis is a rare event leading to ST segment elevation myocardial infarc-
tion and death. Although early thrombosis of drug-eluting and bare metal stents is relatively
frequent, simultaneous thrombosis of bare metal coronary stents has rarely been reported.
Here, we present a case of simultaneous subacute thrombosis of two bare metal stents in
different coronary arteries early after clopidogrel cessation. (Cardiol J 2012; 19, 3: 309–313)
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Introduction
Coronary artery stent thrombosis is a rare com-
plication, mostly presenting as ST segment eleva-
tion myocardial infarction or sudden cardiac death
[1]. Stent thrombosis occurs in approximately 1%
of bare metal stents (BMS) [2]. However, simulta-
neous multivessel stent thrombosis is very rare and
can have catastrophic results. Several factors have
been associated with coronary stent thrombosis
including patient comorbidities, procedural factors,
non-compliance with anti-platelet agents and resis-
tance to anti-platelet medications [2–4]. Of these,
early cessation of dual anti-platelet therapy is the
strongest predictor of stent thrombosis [3].
We present the case of a 56 year-old woman
who underwent percutaneous coronary intervention
(PCI) using BMS in two separate coronary vessels.
Seven days after coronary stenting, simultaneous
thrombosis of two BMSs was observed on coronary
angiography. Although strict adherence to medical
treatment was advised before hospital discharge,
the patient did not take clopidogrel but acetylsali-
cylic acid (ASA). We want to highlight the impor-
tance of strict adherence to anti-platelet medica-
tions to prevent coronary stent thrombosis.
Case report
A 56 year-old woman was admitted to our car-
diology department complaining of exertional chest
pain of three months’ duration which was squeez-
ing in character and radiating to the left arm. She
had had hypertension for six years, was a smoker
(35 pack years), and had a history of transient is-
chemic attack and peripheral artery disease with
critical stenosis at both carotid arteries. Family his-
tory was unremarkable for any cardiovascular ill-
ness. Physical examination was within normal lim-
its except for a mild apical systolic murmur. Com-
plete blood count and serum biochemistry were
within normal limits. Coronary angiography showed
critical stenosis at the middle segment of the left
anterior descending artery (LAD) and proximal
major obtuse marginal (OM) artery (Fig. 1). Suc-
cessful PCI to the mid LAD was performed with
BMS (Multi Link Vision, 2.75 × 15 mm, Abbott
Vascular, Abbott Park, Illinois, USA) and another
BMS (Multi Link Vision, 2.75 × 12 mm, Abbott Vas-
cular, Santa Clara, California, USA) to proximal ma-
jor OM. Final angiography showed TIMI 3 distal flow
without residual stenosis or dissection at both coro-
nary arteries (Fig. 2).
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The patient was discharged with ASA, clopi-
dogrel, ramipril and metoprolol medications three
days after stent implantation. Four days after hospi-
tal discharge, the patient was readmitted to the emer-
gency department with severe chest pain. Electro-
cardiography revealed both anterior and inferolateral
ST segment elevation (Fig. 3). Treatment with ASA
(300 mg), clopidogrel (600 mg), intravenous unfrac-
tioned heparin, metoprolol and atorvastatin was im-
mediately initiated. She was hemodynamically sta-
ble. The patient was taken to the catheter laboratory
for primary PCI which revealed simultaneous stent
thrombosis at LAD and major OM stents (Fig. 4).
The LAD mid occlusion was treated with semi-com-
pliant balloon angioplasty (Sprinter Legend RX Semi-
compliant Balloon, 2.5 × 30 mm, Medtronic, Min-
nesota, USA) followed by a second BMS (Multi Link
Vision, 2.75 × 8 mm) placed proximal to the initial
stent because of dissection after repeated balloon
inflations (Fig. 5). The major OM occlusion was also
treated with balloon angioplasty (Biotronik AG,
2.5 × 20 mm, Bulach, Switzerland). Final angiogra-
phy revealed TIMI 3 flow distal to the coronary
stents. After the intervention, tirofiban therapy was
given for 36 hours. During the hospital stay, complete
blood count, serum biochemistry, hypercoagulable
Figure 1. Coronary angiography showing critical coronary stenosis at major obtuse marginal artery in the left anterior
oblique cranial projection (A) and mid left anterior descending artery in right anterior oblique cranial projection (B) (arrows).
A B
Figure 2. A bare metal stent (Multi Link Vision, 2.75 × 15 mm) was deployed to mid left anterior descending artery
without residual lesion (A) (arrow). Afterwards, another bare metal stent (Multi Link Vision, 2.75 × 12 mm) was
implanted to proximal major obtuse marginal artery stenosis without residual lesion or dissection (B) (arrow).
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Figure 3. Electrocardiography revealed ST segment elevation on both anterior and inferior leads.
Figure 4. Simultaneous coronary stent thrombosis causing complete occlusion proximal to bare metal stent in left
anterior descending artery (A) (arrows) and major obtuse marginal artery (B) (arrows).
Figure 5. After balloon angioplasty with balloon (BiotronicElect 2.5 × 20 mm), TIMI 3 flow was observed (A) (arrow).
For left anterior descending artery lesion, after balloon angioplasty (Sprinter Legend Rx 2.5 × 30 mm), coronary
dissection was observed proximal to left anterior descending artery stent, so a bare metal stent (Multi Link Vision
2.75 × 8 mm) was implanted (B). Final coronary angiography showed TIMI 3 distal flow without residual stenosis
or dissection.
A B
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blood tests including prothrombin time, activated
partial thromboplastin time, international normalized
ratio, protein C activity, protein S (total and free),
antithrombin III, anticardiolipin antibodies, ho-
mocysteine and factor V Leiden mutation were eval-
uated and found to be within normal limits. To rule
out clopidogrel resistance, a test was carried out for
adenosine diphosphase (ADP)-induced platelet ag-
gregation utilizing the VerifyNow P2Y12 point-of-
-care assay (VerifyNow P2Y12 test cartridge system,
Accumetrics, San Diego, California, USA). This re-
vealed a normal response. She was observed as an
inpatient for four days and discharged with a strict
recommendation of dual anti-platelet therapy for at
least one year. A recent three month follow-up
found no significant symptoms and she has complied
with her dual anti-platelet medication.
Discussion
Despite the beneficial role of coronary stent
implantation for obstructive coronary artery lesions,
stent thrombosis has remained a serious complica-
tion of percutaneous interventions either with
a BMS or a drug-eluting stent (DES). Although si-
multanous subacute stent thrombosis after the im-
plantation of two DESs and with one BMS and one
DES have previously been reported, to the best of
our knowledge this is the first case report of simu-
ltaneous subacute thrombosis of two BMSs in two
separate coronary arteries.
Most cases of stent thrombosis occur within
the first month after deployment, irrespective of the
stent type [5]. In a pooled analysis of six coronary
stenting studies, stent thrombosis mostly occurred
within two days of BMS implantation [2]. Several
factors related to the patient, coronary lesion and
percutaneous intervention predispose to stent
thrombosis. Incomplete stent expansion, stent mal-
position, stent length, small vessel caliber, bifurca-
tion lesion, in-stent restenosis lesion, intermediate
(≥ 50% to < 70% stenosis) coronary artery disease
proximal to the culprit lesion and residual thrombus
or persistent dissection after stent placement are the
leading procedural, lesion and stent characteristics
predisposing to coronary stenosis [2, 3, 6, 7].
Acute coronary syndrome, older age, diabetes
mellitus, left ventricular dysfunction, prior brachy-
therapy, malignancy, chronic kidney disease, hyper-
coagulable state, disorders in the metabolism of
anti-platelet agents and adherence to medications
were the main factors related to our patient. Impor-
tantly, the most important predictor for early and
late stent thrombosis is non-adherence to clopi-
dogrel therapy [3].
Adherence to anti-platelet agents plays a key
role in the management of patients after PCI. Dual
anti-platelet therapy with aspirin and clopidogrel is
standard to prevent stent thrombosis. Discontinu-
ation is associated with a marked increase in the
risk of stent thrombosis. Patient non-adherence,
side effects like bleeding, allergic reactions and the
need for invasive or surgical procedures are the
main factors for premature cessation of anti-plate-
let therapy. Furthermore, a patient’s educational
level and the cost of drugs may have an impact on
adherence to optimal medical therapy, especially in
developing countries. Beyond those, the results of
the REGINA survey indicated a dramatic hetero-
genity as to the management of anti-platelet theapy
discontinuation and reintroduction among practitio-
ners interested in anti-platelet therapy, from den-
tists to cardiologists, highlighting the urgent need
to improve practitioners’ basic knowledge [8].
Simultaneous stent thrombosis can be due to
several factors including cessation of anti-platelet
agents, anti-platelet resistance, systemic inflamma-
tory and thrombogenic milieu due to acute coronary
syndromes, or secondary thrombosis due to sys-
temic hypotension after one stent thrombosis.
However, our patient did not have an acute
coronary syndrome which can cause stent throm-
bosis. She was hemodynamically stable on admis-
sion, so hypotension-induced stent thrombosis was
not considered as the cause. The possible etiology
of clopidogrel resistance was excluded by an
ADP-induced platelet aggregation test which re-
vealed a normal response. Hypercoagulable disor-
der was not found after standard coagulation tests.
Periprocedural coronary dissection or stent malpo-
sition was not considered because the patient’s re-
peat catheterization did not reveal any dissection.
An intravascular ultrasound was not performed be-
cause of uneventful intervention with successful an-
giographic results after post-dilatation to high pres-
sure with a semi-compliant balloon.
In our patient, the single most important fac-
tor predisposing to simultaneous BMS thrombosis
seems to have been non-adherence to clopidogrel
therapy.
In conclusion, this case report highlights the im-
portance of strict adherence to anti-platelet medications
after coronary stent implantation. Physicians should
be aware of the factors that contribute to clopidogrel
cessation and patients should be educated about the
dangers of anti-platelet drug discontinuation.
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